GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar

References

• Prescribing information Humira. [cited 2022 Aug 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf.
   Google Scholar
• FDA approved Biosimilar Hyrimoz® (adalimumab). [cited 2022 Aug 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761071s011lbl.pdf
   Google Scholar
• FDA approves Novartis’ copy of AbbVie bestseller Humira. [cited 2022 Aug 1]. Available from: https://www.reuters.com/article/us-abbvie-novartis-fda-idUSKCN1N529J
   Google Scholar
• EMA approved Biosimilar Hyrimoz® (adalimumab). [cited 2022 Aug 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_en.pdf
   Google Scholar
• Schiestl M, Roesli C. Development and analytical characterization of GP2017: a proposed Adalimumab biosimilar. Am J Gastroenterol. 2016;111(S289):S289. Abstract 628.
   Google Scholar
• Kronthaler U, Fritsch C, Hainzl O, et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar Adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18(8):921–930.
   PubMed Web of Science ®Google Scholar
• von Richter O, Lemke L, Haliduola H, et al. GP2017, an Adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;19(10):1075–1083.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler JFsJr., et al. Phase III randomized study of the proposed Adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
   PubMed Web of Science ®Google Scholar
• Wiland P, Jeka S, Dokoupilova E, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. BioDrugs. 2020;34(6):809–823.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gaylis N, et al. Treatment with SDZ-ADL, an Adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS). BioDrugs. 2021;35(2):229–238.
   PubMed Web of Science ®Google Scholar
• Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from Adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903.
   PubMed Web of Science ®Google Scholar
• Raghavan RR, McCombie R ICH Q5E comparability of biotechnological/biological products subject to changes in their manufacturing processes. Summary and Analysis of ICH Q5E Guideline. Book Editor(s): Andrew Teasdale, David Elder, Raymond W. Nims. First published: 27 September 2017. (last accessed on Aug 1st, 2022). 2017.
   Google Scholar
• European Medicines Agency. Humira-Summary of product characteristics. 2017. [cited 2018 Nov 27]: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf
   Google Scholar
• Nader A, Beck D, Noertersheuser P, et al. Population pharmacokinetics and immunogenicity of Adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56(9):1091–1102.
   PubMed Web of Science ®Google Scholar
• Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407–414.
   PubMed Web of Science ®Google Scholar
• Jensen MP, Smith DG, Ehde DM, et al. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. Pain. 2001;91(3):317–322.
   PubMed Web of Science ®Google Scholar
• von Richter O, Lemke L, Haliduola H, et al. Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an Adalimumab biosimilar. Expert Opin Biol Ther. 2019;19(10):1057–1064.
   PubMed Web of Science ®Google Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657–680.
   PubMedGoogle Scholar
• Liu J, Wang Y, Xiong E, et al. Role of the IgM Fc Receptor in Immunity and Tolerance. Front Immunol. 2019;10:529.
   PubMed Web of Science ®Google Scholar
• Hyrimoz summary of product characteristics (last updated: 03-Mar-2022). [online]. [cited 2022 Aug 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz
   Google Scholar
• Webster CJ, Woollett GR. Comment on “the end of phase 3 clinical trials in biosimilars development?” BioDrugs. 2018;32(5):519–521.
   PubMed Web of Science ®Google Scholar
• Sanchez-Felix M, Burke M, Chen HH, et al. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ji P, Li Z, et al. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314–325.
   PubMed Web of Science ®Google Scholar
• Kinnunen HM, Mrsny RJ. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release. 2014;28(182):22–32.
   Google Scholar
• Hassler S, Bachelet D, Duhaze J, et al. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium. Plos Med. 2020;17(10):e1003348.
   PubMed Web of Science ®Google Scholar
• Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68(5):510–521.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [internet]. Hyrimoz. Highlights of prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761071s011lbl.pdf (last accessed on 2022 Aug 1).
   Google Scholar
• Wynne C, Schwabe C, Lemech C, et al. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opin Investig Drugs. 2022;10:1–12.
   Google Scholar
• Yu KS, Jang IJ, Lim HS, et al. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference Adalimumab: a randomized phase I study in healthy subjects. Clin Transl Sci. 2021;14(4):1280–1291.
   PubMed Web of Science ®Google Scholar
• Kang J, Eudy-Byrne RJ, Mondick J, et al. Population pharmacokinetics of Adalimumab biosimilar Adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol. 2020;86(11):2274–2285.
   PubMed Web of Science ®Google Scholar
• Usach I, Martinez R, Festini T, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986–2996.
   PubMed Web of Science ®Google Scholar
• Clair-Jones A S, Prignano F, Goncalves J, et al. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741–757.
   PubMed Web of Science ®Google Scholar
• Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257–270.
   PubMed Web of Science ®Google Scholar
• Pilunni D, Santuccio C, Sottosanti L, et al. Relationship between injection site reactions and different Adalimumab formulations. Analysis of the adverse events reported in Italy in the period 2016-2019. Eur Rev Med Pharmacol Sci. 2021;25(8):3300–3305.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014;16(10):971–976.
   PubMed Web of Science ®Google Scholar
• Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001;18(3):205–207.
   PubMed Web of Science ®Google Scholar
• Ahn SS, Lee M, Baek Y, et al. A randomized pharmacokinetic study in healthy male subjects comparing a high-concentration, citrate-free SB5 formulation (40 mg/0.4 ml) and prior SB5 (Adalimumab Biosimilar). Rheumatol Ther. 2022 Jul 1;9:1157–1169.
   PubMed Web of Science ®Google Scholar
• Davidson A, Brimhall D, Kay J, et al. Randomised, phase I pharmacokinetic study of Adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021;87(11):4323–4333.
   PubMed Web of Science ®Google Scholar